How Do You Know If A REMS Is Effective? Look At Postmarket Data, Surveys, Patient Access
Executive Summary
US FDA draft guidance describes how to determine if a Risk Evaluation and Mitigation Strategy is meeting its goals; another guidance advises how to conduct REMS knowledge surveys.
You may also be interested in...
Waivers For Shared REMS Will Depend On Impact To Generics, Docs, Patients
US FDA will take multiple factors into account when deciding whether single shared-system REMS requirement is necessary.
Shared REMS: US FDA Wants Brisk Brand-Generic Talks, Might Give Unilateral Waivers
New draft guidances are an attempt to curb abuse of REMS single shared system process to delay generic entry.
Rejecting PhRMA's Request, US FDA Sticks With Size Over Function In Defining Biologic
Agency's final rule defines protein based on size of amino acid sequence, irrespective of method of manufacture, saying this 'bright-line rule' provides regulatory certainty.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: